• KOL
    • Chronic Migraine
    • Marcelo Eduardo Bigal
    • Marcelo Eduardo Bigal: Influence Statistics

      Marcelo Eduardo Bigal

      Marcelo Eduardo Bigal

      Show email address

      Ventus Therapeutics, Montreal, Quebec, Canada | Ventus Therapeutics, 100 Beaver St, Suite 202 Waltham, Boston, MA, 02453, USA | Ventus Therapeutics, Montreal, QC, Canada | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Marcelo Eduardo Bigal:Expert Impact

      Concepts for whichMarcelo Eduardo Bigalhas direct influence:Chronic migraine,Preventive treatment,Temporomandibular disorders,Acute treatment,Episodic migraine,Chronic daily headache,Cardiovascular disease,Migraine disorders.

      Marcelo Eduardo Bigal:KOL impact

      Concepts related to the work of other authors for whichfor which Marcelo Eduardo Bigal has influence:Chronic migraine,Headache disorders,Acute treatment,Medication overuse.

      KOL Resume for Marcelo Eduardo Bigal

      Year
      2022

      Ventus Therapeutics, Montreal, Quebec, Canada

      2021

      Ventus Therapeutics, 100 Beaver St, Suite 202 Waltham, Boston, MA, 02453, USA

      Labrys Biologics

      2020

      Ventus Therapeutics, Montreal, Canada

      2019

      Ventus Therapeutics, Montreal, Canada.

      Purdue Pharma, Purdue Pharma, USA.

      2018

      Purdue Pharma, 201 Tresser Boulevard, 06901, Stamford, CT, USA

      From the Department of Biomechanics, Medicine and Locomotor Apparatus Rehabilitation – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil (GFC, LLF, CFP, DB-G); Department of Neurosciences and Behavioral Sciences – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil (FD); and Research and Development Department, Teva Pharmaceuticals, Frazer, Pennsylvania (MEB).

      2017

      Migraine & Headache Clinical Development, Global Branded R&D, Frazer, Pennsylvania

      Teva Pharmaceuticals, North Wales, PA USA

      2016

      Clinical Development, Teva Pharmaceutical Industries Frazer PA USA

      Rummo Benevento Hospital – Neurology Benevento Italy

      Labrys Biologics Inc., Doylestown, PA

      2015

      Migraine & Headache Clinical Development

      Department of Neurology, Albert Einstein College of Medicine, Bronx, NY.

      2014

      Labrys Biologics Doylestown PA USA

      2013

      Labrys Biologics Inc., CA, USA

      Albert Einstein College of Medicine, Department of Neurology, Bronx, NY

      Merck Investigator Studies Program, Scientific Engagements and Education Ribeirão Preto São Paulo Brazil

      2012

      Scientific Engagement and Education (MISP/SEE), North Wales, USA

      Department of Neurology, Albert Einstein College of Medicine, Bronx, New York

      2011

      Albert Einstein College of Medicine, Bronx, U.S

      Merck Research Laboratories, 1 Merck Drive, PO Box 100, 08889, Whitehouse Station, NJ, USA

      2010

      From the Glia Institute (M.A.A.), Ribeirao Preto, São Paulo, Brazil; Department of Child and Adolescent Neurology (V.G., F.G.), Psychiatry and Rehabilitation, Sapienza University of Rome, Italy; Department of Pediatrics (R.C.A.P.A.), São José do Rio Preto School of Medicine, São Paulo, Brazil; Merck Research Laboratories (M.E.B.), Whitehouse Station, NJ; and Department of Neurology (M.E.B.), Albert Einstein College of Medicine, Bronx, NY.

      Merck & Co., Inc, San Diego, CA

      Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.

      Albert Einstein College of Medicine, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Marcelo Eduardo Bigal is among the top experts in the world.
      Concept World rank
      vdt 400 lx #1
      18 brazilian states #1
      mwa iqr #1
      patients fremanezumab #1
      migraine suffer #1
      headaches headache diagnoses #1
      female patients tmds #1
      reasons intranasal administration #1
      questionnaire adverse #1
      migraine greater risk #1
      headache school performance #1
      valid effective migraine #1
      subgroups migraine patients #1
      isometric contractions patients #1
      polytherapy treatment migraine #1
      etth tmd #1
      low rrs vr #1
      vr adolescents #1
      migraine tmd #1
      disorders revised #1
      temporomandibular disorders frequency #1
      115364 #1
      migraine increased frequency #1
      monoclonal cgrp antibody #1
      probable moh pmoh #1
      followup successful detoxification #1
      1 tablet 2 #1
      cgrp centers #1
      presence sleep bruxism #1
      hemicrania autonomic #1
      headaches studies #1
      patients episodic pattern #1
      tolerability lbr101 #1
      topiramate nortriptyline #1
      cdh girls #1
      tmd myofascial tmd #1
      dipyrone aura migraine #1
      mwa 665 95 #1
      uc questions #1
      month cdh #1
      covariates balance parameters #1
      chronic migraine concept #1
      study balance impairments #1
      migraine population #1
      episodic attacks #1
      medication overuse proposal #1
      migraine medical diagnosis #1
      falls balance impairment #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Marcelo Eduardo Bigal

      KOL-Index: 18564

      BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine.

      METHODS: In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine on ≥8 days per month) in a 1:1:1 ratio to receive ...

      Known for Chronic Migraine | Fremanezumab Placebo | Preventive Treatment | Headache Month | Monoclonal Antibodies
      KOL-Index: 16972

      BACKGROUND: Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.

      METHODS: In this multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel-group phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had chronic ...

      Known for Preventive Treatment | Chronic Migraine | Patients Placebo | Safety Tolerability | 675 225
      KOL-Index: 16868

      BACKGROUND: Calcitonin gene-related peptide (CGRP) is a validated target for the treatment of episodic migraine. Here we assess the safety, tolerability, and efficacy of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine.

      METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2b study, we enrolled men and women (aged 18-65 years) from 62 sites in the USA who had migraine headaches 8-14 days per month. ...

      Known for Preventive Treatment | Episodic Migraine | Safety Tolerability | Phase 2b Study | Patients Placebo
      KOL-Index: 16693

      OBJECTIVE: To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.

      METHODS: This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of ...

      Known for Chronic Migraine | Placebo Treatment | Safety Topiramate | 100 Day | Baseline Monthly
      KOL-Index: 16535

      OBJECTIVE: To assess the presence and handicap due to vestibular symptoms in three subgroups of patients with migraine and controls.

      METHODS: Women between 18-55 years old were diagnosed by headache specialists and stratified as migraine with aura (n = 60), migraine without aura (n = 60), chronic migraine (n = 60) and controls (n = 60). Information regarding demographics, headache and vestibular symptoms were collected in this cross-sectional study. The self-perceived handicap related to ...

      Known for Vestibular Symptoms | Chronic Migraine | Presence Aura | Headache Specialists | Adult Cross
      KOL-Index: 16229

      OBJECTIVE: To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease.

      DESIGN: Systematic review and meta-analysis.

      DATA SOURCES: Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009. Selection criteria Case-control and cohort studies investigating the association between any migraine or specific migraine ...

      Known for Cardiovascular Disease | Association Migraine | Myocardial Infarction | Women Risk | Ischaemic Stroke
      KOL-Index: 15775

      Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine.

      Objective: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose.

      Design and Setting: Randomized, double-blind, placebo-controlled, parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient ...

      Known for Fremanezumab Placebo | Monthly Migraine | Baseline Week | Patients Episodic | Clinical Trial
      KOL-Index: 13468

      In the absence of a biological marker and expert consensus on the best approach to classify chronic migraine (CM), recent revised criteria for this disease has been proposed by the Headache Classification Committee of the International Headache Society. This revised criteria for CM is now presented in the Appendix. Herein we field test the revised criteria for CM. We included individuals with transformed migraine with or without medication overuse (TM+ and TM–), according to the criteria ...

      Known for International Classification | Headache Disorders | Revised Criteria | Chronic Migraine | Field Testing
      KOL-Index: 13455

      OBJECTIVE: To describe the patterns of medical treatment for migraineurs in the United States.

      BACKGROUND: Over the past decade, many new treatments for migraine have become available and awareness of migraine has improved. However, there is little information about the patterns of medical treatment in the US society.

      DESIGN/METHODS: A validated self-administered headache questionnaire was mailed to a random sample of 120,000 US households. Each household member with severe headaches was ...

      Known for United States | Preventive Treatment | Migraine Prevalence | Medical Diagnosis | Current Users
      KOL-Index: 13407

      BACKGROUND: Chronic migraine is the most common type of chronic daily headache seen in headache tertiary care centers. Most patients with chronic migraine report their ability to function and feeling of well-being as severely impaired.

      OBJECTIVE: To measure the headache-related disability of patients with chronic migraine using the Migraine Disability Assessment (MIDAS) Questionnaire, comparing it with that obtained in a control group of patients with episodic migraine.

      METHODS: The ...

      Known for Chronic Migraine | Disability Assessment | Midas Questionnaire | Patients Episodic | Daily Headache
      KOL-Index: 13236

      OBJECTIVES: To compare the second edition of the International Classification of Headache Disorders (ICHD-2) and the Silberstein-Lipton (S-L) criteria in the classification of adolescents with chronic daily headache (CDH).

      METHODS: We reviewed the clinical records and the headache diaries of 170 adolescents (13 to 17 years) seen between 1998 and 2003 at a headache center. Relevant information was transferred to a standardized form that included operational criteria for the ICHD-2. CDH ...

      Known for International Classification | Chronic Daily Headache | Medication Overuse | Probable Migraine | Ichd2 Criteria
      KOL-Index: 13120

      Studies suggest that a substantial proportion of headache sufferers presenting to headache clinics may overuse acute medications. In some cases, overuse may be responsible for the development or maintenance of a chronic daily headache (CDH) syndrome. The objectives of this study are to evaluate patterns of analgesic overuse in patients consulting a headache centre and to compare the outcomes in a group of patients who discontinued medication overuse to those of a group who continued the ...

      Known for Transformed Migraine | Medication Overuse | Headache Centre | Clinical Characteristics | 1 2
      KOL-Index: 12710

      Magnesium sulphate has been used in the acute treatment of migraines; some studies found it to be a highly effective medication in the acute control of migraine pain and associated symptoms. This randomized, double-blind, placebo-controlled study assesses the effect of magnesium sulphate on the pain and associated symptoms in patients with migraine without aura and migraine with aura. Sixty patients in each group were assigned at random to receive magnesium sulphate, 1000 mg ...

      Known for Acute Treatment | Migraine Aura | Magnesium Sulphate | Controlled Study | Pain Relief
      KOL-Index: 12451

      BACKGROUND: Dipyrone (Metamizol) has been used in the acute treatment of migraines in Brazil. Some investigators have found it to be a highly effective medication for migraine pain and associated symptoms.

      OBJECTIVE: To conduct a randomized, placebo controlled, double blind study to assess the effect of dipyrone on the pain and symptoms associated with migraine without aura or with aura and the adverse effect profile of this medication.

      METHODS: For the migraine without aura group, 44 ...

      Known for Acute Treatment | Intravenous Dipyrone | Migraine Aura | Controlled Study | 30 Patients

      Key People For Chronic Migraine

      Top KOLs in the world
      #1
      Richard B Lipton
      chronic migraine united states acute treatment
      #2
      Stephen David Silberstein
      chronic migraine cluster headache acute treatment
      #3
      David William Dodick
      chronic migraine cluster headache acute treatment
      #4
      Peter James Goadsby
      cluster headache chronic migraine acute treatment
      #5
      Hanschristoph C Diener
      atrial fibrillation cluster headache chronic migraine
      #6
      Marcelo Eduardo Bigal
      chronic migraine preventive treatment temporomandibular disorders

      Ventus Therapeutics, Montreal, Quebec, Canada | Ventus Therapeutics, 100 Beaver St, Suite 202 Waltham, Boston, MA, 02453, USA | Ventus Therapeutics, Montreal, QC, Canada | Ventus Therapeutics, Montreal, Québec, Canada. | Research and Development, Tev

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.